Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_wilson_lower_bound float32
[ 5 ]	158	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	false	The primary objective is to compare the effectiveness and tolerance of the medication named lubiprostone plus a large volume liquid laxative versus placebo which is a look alike medication that has no effect such as a sugar pill plus a large volume liquid laxative as a bowel cleaning preparation for colonoscopy to see ...	The study is a double blind placebo controlled study of lubiprostone in 4 doses vs look alike placebo in 4 doses before bowel preparation for outpatient screening, surveillance and diagnostic colonoscopy. Patients with severe underlying medical conditions were excluded. Patients with inflammatory bowel disease, frequen...	Colonoscopy	Routine screening colonoscopy Colonoscopy Preparation Amitiza GoLYTELY Pegylated Electrolytes Preparation Solution Colonoscopy Solution	null	2	arm 1: First dose of lubiprostone 24 micrograms or placebo was administered 2 nights before colonoscopy and subsequent doses at breakfast, lunch, and dinner on the day before the procedure. Patients were on a clear liquid diet on the day before the procedure and were instructed to initiate drinking PEG (immediately aft...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total intervention 2: Amitiza Placebo	intervention 1: lubiprostone (Amitiza) intervention 2: Placebo	3	Detroit \| Michigan \| United States \| -83.04575 \| 42.33143 Novi \| Michigan \| United States \| -83.47549 \| 42.48059 West Bloomfield \| Michigan \| United States \| -83.38356 \| 42.56891	123	NCT00645801	1COMPLETED	2011-07-01	2008-03-01	Henry Ford Health System	7OTHER	false	false	false	null	0
[ 3 ]	23	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity. Protein A immunoadsorption is a dialysis-like technique selectively removing the antibodies from patient's blood. Rituximab is a synthetic antibody capable of destroy...	null	Pemphigus	pemphigus rituximab immunoadsorption dexamethasone treatment management	null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks Rituximab: 1000 mg i.v. given twice at a 2-week interval Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks Azathioprine: 2.5 mg/kg body weight daily p.o.	intervention 1: Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine	1	Lübeck \| Schleswig-Holstein \| Germany \| 10.68729 \| 53.86893	23	NCT00656656	1COMPLETED	2011-07-01	2008-01-01	University of Luebeck	7OTHER	false	false	false	null	0
[ 3 ]	95	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	2MALE	true	This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression. The study is blinded, and subjects w...	null	Prostate Cancer		null	2	arm 1: Bicalutamide 150mg + ZD6474 300mg arm 2: Bicalutamide 150mg + placebo	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 300mg orally, once daily intervention 2: 150mg orally, once daily intervention 3: orally, once daily	intervention 1: ZD6474 (Vandetanib) intervention 2: Bicalutamide intervention 3: Placebo	5	Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Créteil \| N/A \| France \| 2.46569 \| 48.79266 Paris \| N/A \| France \| 2.3488 \| 48.85341 Reims \| N/A \| France \| 4.02853 \| 49.26526 Villejuif \| N/A \| France \| 2.35992 \| 48.7939	95	NCT00659438	1COMPLETED	2011-07-01	2008-02-01	Genzyme, a Sanofi Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	50	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m\^2, and cisplatin 75 mg/m\^2 on Day 1 of each 3-...	null	Non-small Cell Lung Cancer		null	1	arm 1: Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m\^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease ...	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: Bevacizumab was supplied as a sterile liquid in glass vials. intervention 2: Bevacizumab was supplied as a sterile liquid in glass vials. intervention 3: Bevacizumab was supplied as a sterile liquid in glass vials.	intervention 1: Bevacizumab intervention 2: Cisplatin intervention 3: Docetaxel	14	Palma de Mallorca \| Balearic Islands \| Spain \| 2.65024 \| 39.56939 Cadiz \| Cadiz \| Spain \| -6.2891 \| 36.52672 Castellon \| Castellon \| Spain \| -0.04935 \| 39.98567 Donostia / San Sebastian \| Guipuzcoa \| Spain \| -1.97499 \| 43.31283 Alcalá de Henares \| Madrid \| Spain \| -3.35996 \| 40.48205 Madrid \| Madrid \| Spain \| -3.70256 ...	49	NCT00661778	1COMPLETED	2011-07-01	2007-07-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 0 ]	25	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	false	This research is being done to study how the immune system in the small intestine improves after taking antiretroviral (anti-HIV) medications. The main purpose is to measure the increase in the numbers of immune cells in the intestine to see if one type of HIV medication gives different results than other types of HIV ...	While the world-wide AIDS epidemic continues to impact millions of individuals, effective anti-HIV medications have substantially reduced morbidity and mortality for those patients able to adhere to combination regimens. Despite improved survival, durable virologic suppression, and increases in peripheral CD4+T-cell co...	HIV Infections AIDS	HIV Positive AIDS Antiretroviral Therapy Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution treatment experienced	null	3	arm 1: HIV Negative volunteers arm 2: HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications arm 3: HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other...	[ 4, 1, 1 ]	2	[ 0, 0 ]	intervention 1: 400mg tablet twice daily by mouth for nine months intervention 2: 600mg capsule once daily by mouth without regard to food	intervention 1: raltegravir intervention 2: efavirenz	2	Sacramento \| California \| United States \| -121.4944 \| 38.58157 Sacramento \| California \| United States \| -121.4944 \| 38.58157	25	NCT00661960	1COMPLETED	2011-07-01	2008-03-01	University of California, Davis	7OTHER	false	false	false	null	0
[ 3 ]	42	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form. Tandutinib and Bevacizumab are experimental drugs that may prevent new blood vessel formation and thereby slow or stop tumor g...	Background Bevacizumab is a monoclonal antibody directed against vascular- endothelial growth factor (VEGF), the major angiogenesis factor involved in high-grade glioma-mediated angiogenesis. Preclinical studies in our laboratory and others have shown potent antiglioma activity in vivo and early clinical trials of bev...	Glioblastoma Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma	Brain Tumor Chemotherapy Radiation Anti-Angiogenesis Glioblastoma Glioma	null	2	arm 1: GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks. arm 2: AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutin...	[ 0, 0 ]	3	[ 2, 0, 3 ]	intervention 1: Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks. intervention 2: Tandutinib 500 mg by mouth daily dose twice a day. intervention 3: Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.	intervention 1: Bevacizumab intervention 2: MLN-518 (Tandutinib) intervention 3: Quality-of-life assessment	1	Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	42	NCT00667394	1COMPLETED	2011-07-01	2008-04-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 3 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.	PRIMARY OBJECTIVES: I. To determine the objective response rate to cilengitide in younger patients with recurrent or progressive high-grade glioma that is refractory to standard therapy. SECONDARY OBJECTIVES: I. To estimate the distribution of time to progression, time to treatment failure, and time to death in thes...	Childhood High-grade Cerebellar Astrocytoma Childhood High-grade Cerebral Astrocytoma Recurrent Childhood Anaplastic Astrocytoma Recurrent Childhood Anaplastic Oligoastrocytoma Recurrent Childhood Anaplastic Oligodendroglioma Recurrent Childhood Brain Tumor Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood...		null	1	arm 1: Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.	[ 0 ]	3	[ 0, 10, 10 ]	intervention 1: Given IV intervention 2: Correlative studies intervention 3: Correlative studies	intervention 1: cilengitide intervention 2: laboratory biomarker analysis intervention 3: pharmacological study	20	Oakland \| California \| United States \| -122.2708 \| 37.80437 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Boston \| Massachusetts \| United States \| -71.05977 \| 42.3...	29	NCT00679354	1COMPLETED	2011-07-01	2008-06-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 2 ]	13	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)	null	Lupus Nephritis		null	3	arm 1: None arm 2: None arm 3: Open-label long-term extension phase	[ 2, 1, 5 ]	3	[ 0, 0, 0 ]	intervention 1: Infusion, Intravenous, single dose, Day 1 intervention 2: Infusion, Intravenous, 30mg/kg, single dose, Day 1 intervention 3: Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study	intervention 1: Placebo intervention 2: Abatacept intervention 3: Abatacept	1	Shanghai \| Shanghai Municipality \| China \| 121.45806 \| 31.22222	9	NCT00705367	1COMPLETED	2011-07-01	2008-08-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0
[ 3 ]	57	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to explore the impact of vitamin D3 on the expression of alpha interferon (IFN alpha) expression in systemic lupus erythematosus (SLE) patients with vitamin D deficiency.	Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies with subsequent immune complex deposition and tissue inflammation. The role of interferon (IFN) alpha in the development of SLE has been repeatedly documented. Vitamin D deficiency is common among lupus patient...	Systemic Lupus Erythematosus SLE Lupus	Systemic lupus erythematosus SLE Vitamin D3 Vitamin D deficiency IFN alpha expression	null	3	arm 1: Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks. arm 2: Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks. arm 3: Participants in this arm take a vitamin D3 placebo ...	[ 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: 8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight intervention 2: 86% microcrystalline cellulose, 14% fumed silica by weight	intervention 1: Vitamin D3 intervention 2: Vitamin D3 placebo	8	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Manhassett \| New York \| United States \| N/A \| N/A Rochester \| New York \| United States \| -77.61556 \| 43.15478 Durham \| North Caroli...	54	NCT00710021	1COMPLETED	2011-07-01	2008-11-01	National Institute of Allergy and Infectious Diseases (NIAID)	0NIH	false	false	false	null	0
[ 5 ]	87	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	This 2 arm study will compare the efficacy and safety of switching to CellCept combined with different regimens of reduced calcineurin inhibitors (CNI) in patients with liver transplants. Patients currently receiving CNI treatment will be randomized into one of 2 groups to receive either 1) CellCept 2.0g/day po bid + 5...	null	Liver Transplantation		null	2	arm 1: Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52. arm 2: Participants received MMF, 1.5 to 2.0 g daily, PO, BID ...	[ 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: 1.5 to 2.0 g daily PO BID intervention 2: 50% reduction from BL intervention 3: ≥75% reduction from BL	intervention 1: Mycophenolate mofetil intervention 2: CNI (50%) intervention 3: CNI (≥75%)	11	Beijing \| N/A \| China \| 116.39723 \| 39.9075 Beijing \| N/A \| China \| 116.39723 \| 39.9075 Changsha \| N/A \| China \| 112.97087 \| 28.19874 Chengdu \| N/A \| China \| 104.06667 \| 30.66667 Chongqing \| N/A \| China \| 106.55771 \| 29.56026 Guangzhou \| N/A \| China \| 113.25 \| 23.11667 Jiangsu \| N/A \| China \| N/A \| N/A Shanghai \| N/A \|...	83	NCT00717314	1COMPLETED	2011-07-01	2008-05-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 3 ]	14	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.	null	Myasthenia Gravis		null	2	arm 1: eculizumab arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses intervention 2: Placebo IV weekly for 4 doses then every two weeks for 7 doses	intervention 1: eculizumab intervention 2: Placebo	25	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Orange \| California \| United States \| -117.85311 \| 33.78779 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Indianapolis \| India...	26	NCT00727194	6TERMINATED	2011-07-01	2008-10-01	Alexion Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	101	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.	The objective of this study is to gain tolerability and efficacy data for Norvir-boosted Lexiva versus Sustiva, both used in combination with Epzicom, as components of a first-line, once daily regimen for the treatment of HIV-1 infection in a patient population that is underrepresented in US clinical research.	Human Immunodeficiency Virus Infections		null	2	arm 1: Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg). arm 2: QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg) The intervention may be switched for the following reasons: * To resolve a Grade 3 or 4 Adverse Event * The subject experienced a virologic failure (as defined in section 3.6.2) * The investigator believes the sub...	intervention 1: Efavirenz 600mg intervention 2: Boosted Lexiva	1	Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511	101	NCT00727597	1COMPLETED	2011-07-01	2008-07-01	Georgetown University	7OTHER	false	false	false	null	0
[ 3 ]	9	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Obsessive-compulsive disorder (OCD) is a common psychiatric illness that affects up to 2-3% of the population. People with OCD experience anxiety-provoking, intrusive thoughts, known as obsessions, and feel compelled to perform repetitive behaviors, or compulsions. The only medications proven effective for OCD are sero...	null	Obsessive Compulsive Disorder	OCD	null	1	arm 1: Minocycline (NPL-2003)	[ 0 ]	1	[ 0 ]	intervention 1: Minocycline (NPL-2003) daily for 12 weeks	intervention 1: NPL-2003	1	New York \| New York \| United States \| -74.00597 \| 40.71427	9	NCT00728923	1COMPLETED	2011-07-01	2008-08-01	New York State Psychiatric Institute	7OTHER	false	false	false	null	0
[ 4 ]	48	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	false	This study involves research. Pregabalin is a Food and Drug Administration (FDA) medication approved in the United States for the treatment of nerve pain related to diabetes and post-herpetic neuralgia "shingles", and for seizures in adults. The purpose of this research is to study the effect of oral Pregabalin on spin...	Gabapentin and the related more potent compound pregabalin have been shown to reduce postoperative pain in animal models (1). Pregabalin given before and after surgery reduced opioid use following spinal fusion surgery (2). Studies have identified the alpha 2 delta auxiliary subunit of voltage-gated calcium channels as...	PAIN	Pregabalin CSF Neurotransmitter	null	3	arm 1: Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose. arm 2: Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at ...	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose. Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses ...	intervention 1: Pregabalin intervention 2: Pregabalin intervention 3: Placebo	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	48	NCT00729690	1COMPLETED	2011-07-01	2008-08-01	Asokumar Buvanendran	7OTHER	false	false	false	null	0
[ 0 ]	94	RANDOMIZED	FACTORIAL	null	4QUADRUPLE	true	2MALE	false	This study will explore the hypothesis that effects of alcohol are in part mediated by increased production of neuroactive steroids, which interact with GABAA-receptors. We propose to study non-dependent drinkers using a 4-session within-subjects design in which alcohol / placebo is paired with dutasteride / placebo pr...	Alcohol has multiple pharmacological effects, though which of these effects relate to the risk of alcohol dependence is not clear. Animal studies indicate that the neuroactive steroid allopregnanolone is an alcohol-modulated endogenous agonist at GABAA receptors and that genetic variation in steroid 5a-reductase type I...	Alcohol Related Disorders Alcoholism Alcohol Abuse	steroid 5Alpha Reductase dutasteride neuroactive steroid	null	4	arm 1: None arm 2: None arm 3: None arm 4: None	[ 2, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes intervention 2: placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes intervention 3: 4 mg...	intervention 1: dutasteride + ethanol intervention 2: placebo medication + ethanol intervention 3: dutasteride + placebo alcohol intervention 4: placebo medication + placebo alcohol	1	Farmington \| Connecticut \| United States \| -72.83204 \| 41.71982	320	NCT00734656	1COMPLETED	2011-07-01	2007-03-01	UConn Health	7OTHER	false	false	false	null	0
[ 0 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	false	The overall goal of the present project is to investigate whether lisdexamphetamine (LDX; Vyvanse) is an effective adjunct to nicotine replacement therapy (NRT) to promote smoking cessation in patients with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and nicotine dependence. The investigators hypothesized ...	This will be a 2-group, parallel, placebo-controlled, double blind study. Regular, nicotine dependent individuals with ADHD will receive NRT pretreatment for 2 weeks prior to an identified quit date.At the quit date, subjects will be randomized into one of two groups. * The first group will begin treatment for 1 week ...	Attention Deficit Hyperactivity Disorder Nicotine Dependence	ADHD Smoking	null	2	arm 1: The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date. arm 2: The second group will receive matching placebo and NRT...	[ 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week. intervention 2: Subjects on this arm will receive Lis-dexamphetam...	intervention 1: Transdermal Nicotine Patch intervention 2: Lis-dexamphetamine (Vyvanse) intervention 3: Placebo	1	Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	32	NCT00736255	1COMPLETED	2011-07-01	2007-12-01	Duke University	7OTHER	false	false	false	null	0
[ 0 ]	46	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.	null	Virus Diseases HIV	Safety	null	2	arm 1: Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir arm 2: Group 2 Continue the same regimen without change	[ 0, 4 ]	1	[ 0 ]	intervention 1: This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented...	intervention 1: Switch NRTIs as a Backbone to Raltegravir	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	46	NCT00749580	1COMPLETED	2011-07-01	2008-11-01	University of South Florida	7OTHER	false	false	false	null	0
[ 4 ]	1,681	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This open-label, single arm study will investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biologic disease modifying antirheumatic drugs (DMARDs), in patients with severe active RA. Patients will receive tocilizumab 8mg/kg iv as a 60 minute infusion every 4 wee...	null	Rheumatoid Arthritis		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 8mg/kg iv (60 minute infusion)	intervention 1: tocilizumab [RoActemra/Actemra]	282	Canberra \| Australian Capital Territory \| Australia \| 149.12807 \| -35.28346 Coffs Harbour \| New South Wales \| Australia \| 153.11351 \| -30.29626 Kogarah \| New South Wales \| Australia \| 151.13564 \| -33.9681 Parramatta Park \| New South Wales \| Australia \| N/A \| N/A Adelaide \| South Australia \| Australia \| 138.59863 \| -34....	1,681	NCT00750880	1COMPLETED	2011-07-01	2008-09-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 5 ]	515	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	null	The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period. Secondary objective was to assess the effect of insulin glargine in comparison with sitagliptin on: * HbA1c level * Fasting Pl...	null	Diabetes Mellitus, Type 2		null	2	arm 1: Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\<FPG≤100mg/dL (3.9mmol/L\<FPG≤5.5mmol/L). arm 2: Dose of 100 mg once a day administered with or without...	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL). intervention 2: Oral administration. 100 mg film-coated tablets. intervention 3: Patients continued with metformin as usual oral anti-diabetic treatment.	intervention 1: Insulin Glargine intervention 2: Sitagliptin intervention 3: Metformin	17	Bridgewater \| New Jersey \| United States \| -74.64815 \| 40.60079 Vienna \| N/A \| Austria \| 16.37208 \| 48.20849 São Paulo \| N/A \| Brazil \| -46.63611 \| -23.5475 Bogotá \| N/A \| Colombia \| -74.08175 \| 4.60971 Cairo \| N/A \| Egypt \| 31.24967 \| 30.06263 Kallithea \| N/A \| Greece \| 23.7 \| 37.95 Hong Kong \| N/A \| Hong Kong \| 114.1...	501	NCT00751114	1COMPLETED	2011-07-01	2008-11-01	Sanofi	4INDUSTRY	false	false	false	null	0
[ 3 ]	44	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.	null	Gastroparesis		null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: 10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily	intervention 1: Domperidone	1	New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815	44	NCT00760461	6TERMINATED	2011-07-01	2008-10-01	Yale University	7OTHER	false	false	false	null	0
[ 0 ]	8	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Kaletra (a combination drug with lopinavir and ritonavir) is one of a few effective medications that are approved and available for young children who are HIV+. The liquid form is reported to have a very nasty taste and presents difficulties for the children who must take the medication twice a day and for their parent...	null	HIV Infections	HIV Kaletra treatment Experienced	null	1	arm 1: Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)	[ 0 ]	1	[ 0 ]	intervention 1: Lopinavir/Ritonavir tablets 100mg/25mg	intervention 1: Low dose Kaletra tablets	1	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838	8	NCT00762320	1COMPLETED	2011-07-01	2008-10-01	Phoenix Children's Hospital	7OTHER	false	false	false	null	0
[ 3 ]	501	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	true	RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about differences in DNA and predict how well patients will respond to treatment and plan better treatment. PURPOSE: This clinical trial is studying blood samples from women with breast cancer or ductal carcino...	OBJECTIVES: Primary * To evaluate the change in endoxifen levels after an increase in tamoxifen citrate dose from 20 mg to 40 mg in women with breast cancer or ductal breast carcinoma in situ with intermediate-metabolizing CYP2D6 genotypes. Secondary * To evaluate the tolerability of increasing the dose of tamoxife...	Breast Cancer Menopausal Symptoms	menopausal symptoms recurrent breast cancer stage I breast cancer stage II breast cancer stage IIIA breast cancer stage IIIB breast cancer stage IIIC breast cancer stage IV breast cancer ductal breast carcinoma in situ breast cancer in situ	null	2	arm 1: One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg. arm 2: This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.	[ 0, 1 ]	5	[ 0, 6, 10, 10, 3 ]	intervention 1: Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis. intervention 2: Genetic analysis of blood sample. intervention 3: Genetic analysis of blood sample. intervention 4: Questionnaire called the survey of participants. Questionnaires...	intervention 1: tamoxifen citrate intervention 2: gene expression analysis intervention 3: pharmacogenomic studies intervention 4: questionnaire administration intervention 5: quality-of-life assessment	7	Chapel Hill \| North Carolina \| United States \| -79.05584 \| 35.9132 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403 Greensboro \| North Carolina \| United States \| -79.79198 \| 36.07264 Greenville \| North Carolina \| United States \| -77.36635 \|...	480	NCT00764322	1COMPLETED	2011-07-01	2008-06-18	UNC Lineberger Comprehensive Cancer Center	7OTHER	false	false	false	null	0
[ 2 ]	10	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts. with relapsed or refractory CTCL. Relapsed or refractory CTCL patients will be newly enrolled in Part II.	null	Lymphoma		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.	intervention 1: vorinostat	0	null	10	NCT00771472	1COMPLETED	2011-07-01	2008-08-01	Merck Sharp & Dohme LLC	4INDUSTRY	false	false	false	null	0
[ 4 ]	459	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined as add-on controller therapy on top of usual...	null	Asthma		null	2	arm 1: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution arm 2: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo intervention 2: Matching placebo	intervention 1: tiotropium 5mcg/day intervention 2: placebo	73	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Riverside \| California \| United States \| -117.39616 \| 33.95335 San Diego \| California \| United States \| -117.16472 \| 32.71571 Waln...	459	NCT00772538	1COMPLETED	2011-07-01	2008-10-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	148	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that ...	null	Systemic Sclerosis Scleroderma	Scleroderma, Diffuse Scleroderma, Limited Scleroderma, Systemic Ulcer prostacyclin	null	2	arm 1: Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose. arm 2: Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's max...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID) intervention 2: None	intervention 1: treprostinil diethanolamine intervention 2: placebo	30	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Farmington \| ...	147	NCT00775463	1COMPLETED	2011-07-01	2009-05-01	United Therapeutics	4INDUSTRY	false	false	false	null	0
[ 4 ]	453	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo. Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined as add-on controller therapy on top of usual...	null	Asthma		null	2	arm 1: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution arm 2: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution intervention 2: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placeb...	intervention 1: tiotropium 5mcg/day intervention 2: placebo	75	Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Fresno \| California \| United States \| -119.77237 \| 36.74773 Stockton \| California \| United States \| -121.29078 \| 37.9577 Waterbury \| Connecticut \| United States \| -73.0515 \| 41.55815 Pensacola \| Florida \| United States \| -87.21691 \| 30.42131 Chicago \|...	453	NCT00776984	1COMPLETED	2011-07-01	2008-10-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 0 ]	148	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	true	The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.	It is the specific aim of this pilot study to assess the feasibility of achieving and maintaining a serum P less than or equal to 3.5 mg/dL (1.13 mmol/L) in patients with eGFR \>20 and \<45 mL/min with any of the 3 commercially available P lowering agents (calcium acetate, sevelamer carbonate, or lanthanum carbonate). ...	Chronic Kidney Disease	phosphorus secondary hyperparathyroidism vascular calcification	null	4	arm 1: 667 mg with meals arm 2: 500 mg with meals arm 3: 800 mg with meals arm 4: with meals	[ 1, 1, 1, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None intervention 4: None	intervention 1: Calcium acetate intervention 2: Lanthanum Carbonate intervention 3: Sevelamer Carbonate intervention 4: Placebo	1	Denver \| Colorado \| United States \| -104.9847 \| 39.73915	145	NCT00785629	1COMPLETED	2011-07-01	2009-02-01	Denver Nephrologists, P.C.	7OTHER	false	false	false	null	0
[ 4 ]	240	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.	null	Chronic Schizophrenia	Schizophrenia SM-13496 Latuda Lurasidone	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Lurasidone 40-160 mg/day flexibly dosed. intervention 2: Quetiapine XR 200-800 mg/day flexibly dosed.	intervention 1: Lurasidone HC1 intervention 2: Quetiapine XR	65	Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Cerritos \| California \| United States \| -118.06479 \| 33.85835 Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Escondido \| California \| United States \| -117.08642 \| 33.11921 Garden ...	292	NCT00789698	1COMPLETED	2011-07-01	2008-12-01	Sumitomo Pharma America, Inc.	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This trial will test the hypothesis that CF102 can safely and effectively suppress viral load in patients with chronic hepatitis C and high circulating levels of virus. The trial will monitor the safety of twice-daily oral dosing with CF102 over a 16-week period; will measure changes in viral load during therapy; and w...	This is a Phase 1/2, randomized, double-blind, placebo-controlled, dose-escalation study of subjects with chronic hepatitis C genotype 1. Eligible subjects will be assigned in a 3:1 ratio (8 subjects in each cohort) to receive qd or bid treatment for 15 days with oral CF-102 or with placebo. Dose escalation will occur ...	Chronic Hepatitis C	Hepatitis C Viral hepatitis	null	4	arm 1: CF102 1 mg qd arm 2: CF102 1 mg bid arm 3: CF102 1 mg bid; 16 weeks arm 4: None	[ 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Oral capsules intervention 2: Matching placebo capsules	intervention 1: CF 102 intervention 2: Placebo	1	Tel Aviv \| N/A \| Israel \| 34.78057 \| 32.08088	32	NCT00790673	1COMPLETED	2011-07-01	2009-07-01	Can-Fite BioPharma	4INDUSTRY	false	false	false	null	0
[ 3 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	true	N-methyl-D-aspartate (NMDA)-type glutamate receptors are thought to play a pivotal role in neurocognitive dysfunction associated with schizophrenia. Further, several novel glutamate-based classes of compound are presently in development as potential novel treatments for persistent negative and cognitive symptoms. The s...	16 in- or outpatients with DSM-IV-TR schizophrenia or schizoaffective disorder and prominent negative symptoms will be recruited for this study. This study will consist of a randomized trial of D-serine (60 mg/kg/d) vs. placebo using a crossover design with a 2-week baseline lead-in, and two 6-week intervention arms se...	Schizophrenia Schizoaffective Disorder	biomarker EEG schizophrenia NMDA D-serine	null	2	arm 1: 60 mg/kg/day arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 60 mg/kg/day intervention 2: oral	intervention 1: D Serine intervention 2: Placebo	1	Orangeburg \| New York \| United States \| -73.94958 \| 41.04649	16	NCT00817336	1COMPLETED	2011-07-01	2009-06-01	Nathan Kline Institute for Psychiatric Research	7OTHER	false	false	false	null	0
[ 5 ]	32	RANDOMIZED	CROSSOVER	5SCREENING	0NONE	true	0ALL	true	This study will measure the percentage of platelet aggregation inhibition with a loading dose of clopidogrel (300 mg) using the VerifyNow Assay System in healthy volunteers who have drank 11 oz of grapefruit juice. It will also measure the percentage of platelet aggregation inhibition with a maintenance dose of clopido...	This study will examine the effect of GFJ on the loading dose (300 mg) of clopidogrel and will evaluate the effect of GFJ on the maintenance dose (75 mg/day) of clopidogrel. Subjects will be randomized to either initially receive GFJ prior to their loading dose of clopidogrel or receive GFJ prior to their second loadin...	Healthy	Platelet Aggregation Inhibition	null	2	arm 1: Participants received a 300 mg dose of clopidogrel with or without GFJ. arm 2: Participants received clopidogrel 75 mg/day for 7 days with or without GFJ	[ 0, 0 ]	3	[ 7, 0, 0 ]	intervention 1: Participants received grapefruit juice during 1 of the 2 periods. intervention 2: None intervention 3: None	intervention 1: Grapefruit juice intervention 2: Clopidogrel 75 mg/day intervention 3: Clopidogrel 300 mg	1	Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626	32	NCT00817999	1COMPLETED	2011-07-01	2008-11-01	Creighton University	7OTHER	false	false	false	null	0
[ 5 ]	602	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	true	Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered rectally,...	This study is a multi-center, randomized, placebo-controlled, double-blinded clinical trial of rectal indomethacin in the prevention of post-ERCP pancreatitis in high risk patients.	Post-ERCP Pancreatitis		null	2	arm 1: Indomethacin suppository arm 2: Placebo suppository	[ 1, 2 ]	2	[ 0, 10 ]	intervention 1: 100 mg PR once at the time of ERCP intervention 2: 2 placebo suppositories at the time of ERCP	intervention 1: Indomethacin intervention 2: Placebo suppositories	4	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Lexington \| Kentucky \| United States \| -84.47772 \| 37.98869 Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	602	NCT00820612	6TERMINATED	2011-07-01	2009-01-01	University of Michigan	7OTHER	false	false	false	null	0
[ 5 ]	19	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	1FEMALE	false	The study examined the effects of adding the sleep aid eszopiclone to Lexapro on mood and levels of the neurotransmitters glutamate, glutamine, and GABA in women with depression, anxiety, and insomnia. Specifically, the objective was to determine the role of glutamate, glutamine, and GABA in mediating the response the ...	null	Depression Anxiety Insomnia	Magnetic Resonance Spectroscopy Glutamate Glutamine GABA Lexapro Lunesta Escitalopram Eszopiclone	null	2	arm 1: Lexapro for 10 weeks together with eszopiclone. arm 2: Lexapro for 10 weeks together with placebo.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone. intervention 2: Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for...	intervention 1: Eszopiclone intervention 2: Placebo	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	19	NCT00826111	1COMPLETED	2011-07-01	2007-08-01	Steward St. Elizabeth's Medical Center of Boston, Inc.	7OTHER	false	false	false	null	0
[ 3 ]	129	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients. Based on the results from this study, a confirmatory phase 3 study may be conducted.	null	Human Immunodeficiency Virus-1	CCR5-tropic HIV-1 virus	null	2	arm 1: maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, ...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) O...	intervention 1: maraviroc intervention 2: maraviroc	39	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Norwalk \| Connecticut \| United States \| -73.4079 \| 41.1176 W...	121	NCT00827112	1COMPLETED	2011-07-01	2009-03-01	ViiV Healthcare	4INDUSTRY	false	false	false	null	0
[ 3 ]	50	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to examine the effects of propranolol versus placebo on responses to cocaine cues in cocaine dependent individuals.	This study will employ cocaine-dependent individuals to investigate the acute effects of propranolol vs. placebo, administered immediately after a retrieval session of cocaine cue exposure, on the subjective and physiological responses occurring during a subsequent test session of cocaine cue exposure. Participants (N=...	Cocaine Dependence	cocaine cocaine-dependent propranolol craving beta-blockade cue exposure drug addiction memory addictive behavior	null	2	arm 1: None arm 2: None	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 40 mg administered once intervention 2: administered once	intervention 1: Propranolol intervention 2: Placebo	1	Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632	51	NCT00830362	1COMPLETED	2011-07-01	2009-02-01	Medical University of South Carolina	7OTHER	false	false	false	null	0
[ 3 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	1.1 Primary Objective To evaluate the effects of short course preoperative erlotinib treatment in a panel of predictive biomarkers from a group of patients who undergo resection of pancreatic adenocarcinoma with curative intent. 1.2 Secondary Objectives 1.2.1 To analyze the effects of short course preoperative erlot...	Our current clinical trial proposal includes a short course of pre-operative, single agent erlotinib followed by post-operative erlotinib-gemcitabine in a neo-adjuvant/adjuvant approach to the treatment of patients with resectable pancreatic adenocarcinoma. The short course pre-operative erlotinib treatment serves two ...	Pancreatic Cancer	Pancreatic Cancer Assay Biomarkers	null	1	arm 1: 150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles	[ 0 ]	1	[ 0 ]	intervention 1: Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.	intervention 1: erlotinib	1	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066	19	NCT00841035	6TERMINATED	2011-07-01	2009-02-01	University of Alabama at Birmingham	7OTHER	false	false	false	null	0
[ 3 ]	16	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	true	0ALL	false	This research is designed to assess the impact of pretreatment with puerarin (NPI-031G), a major ingredient in the plant kudzu, on alcohol drinking. Hypothesis: Short-term treatment with this compound will reduce alcohol self-administration in a simulated natural settings laboratory.	Participants will have an opportunity to drink up to 6 beers, plus water and juice, during a 90 minute afternoon drinking session in our simulated apartment room laboratory. Drinking sessions will be conducted in the afternoon after participants take puerarin or placebo for 7 days.	Alcohol Abuse		null	2	arm 1: None arm 2: Sugar beet filler in capsule	[ 1, 2 ]	1	[ 0 ]	intervention 1: 400 mg, three times a day for 7 days	intervention 1: Puerarin, Placebo	1	Belmont \| Massachusetts \| United States \| -71.17867 \| 42.39593	16	NCT00854724	1COMPLETED	2011-07-01	2009-02-01	Mclean Hospital	7OTHER	false	false	false	null	0
[ 3 ]	1	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	ON 01910.Na has undergone preclinical and clinical phase I studies showing activity in patients with progressing ovarian cancer resistant to platinum-based chemotherapies. This study will look at a larger population of patients to determine whether treatment with ON 01910.Na has an effect on progression free survival r...	This is a Phase II single arm study of ON 01910.Na to be administered as a 2-hour infusion biweekly to patients with progressive ovarian cancer resistant to platinum-based therapy. The primary objective is to evaluate progression-free survival (PFS). The secondary objectives are to document other measures of outcome \...	Ovarian Cancer	Ovarian Cancer Cisplatin Carboplatin	null	1	arm 1: 3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: ON 01910.Na	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	1	NCT00856791	1COMPLETED	2011-07-01	2009-03-01	Traws Pharma, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	486	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	A multi center, randomized study to evaluate the efficacy and safety of eszopiclone compared to placebo in children (6-11 years of age, inclusive) and adolescents (12-17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.	This is a multi center, randomized, double blind, placebo controlled, fixed dose study of eszopiclone in pediatric subjects 6-17 years of age, inclusive, with ADHD associated insomnia. Subjects will be randomized at approximately 1:1:1 to either low dose oral eszopiclone (1 mg for children ages 6-11 years, 2 mg for ado...	Insomnia Attention Deficit Hyperactivity Disorder	Hypnotic Eszopiclone Attention Deficit/Hyperactivity Disorder Insomnia Children Adolescent Polysomnography Actigraphy	null	3	arm 1: 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years arm 2: 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years arm 3: Placebo 6-17 years	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years intervention 2: 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years intervention 3: 1 tablet per day for 12 weeks	intervention 1: eszopiclone intervention 2: eszopiclone intervention 3: Placebo	73	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Dothan \| Alabama \| United States \| -85.39049 \| 31.22323 Chandler \| Arizona \| United States \| -111.84125 \| 33.30616 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| Unite...	483	NCT00856973	1COMPLETED	2011-07-01	2009-05-01	Sumitomo Pharma America, Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	141	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary rationale for this study is to evaluate the effect of once daily montelukast on duration of acute illness in infants with first-time bronchiolitis.	null	Bronchiolitis	Bronchiolitis montelukast leukotriene inhibitor	null	2	arm 1: 4mg granules PO QD for 14 days arm 2: Sucrose granules PO QD for 14 days	[ 0, 2 ]	2	[ 0, 10 ]	intervention 1: 4mg granules daily for 14 days intervention 2: table sugar as placebo daily for 14 days	intervention 1: montelukast sodium intervention 2: sucrose	1	Milwaukee \| Wisconsin \| United States \| -87.90647 \| 43.0389	141	NCT00863317	1COMPLETED	2011-07-01	2008-12-01	Medical College of Wisconsin	7OTHER	false	false	false	null	0
[ 2, 3 ]	8	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study will test the efficacy of a systematic, multi-modal intervention protocol designed to improve sleep functioning and subsequent alleviation of daytime cognitive and behavioral difficulties among children diagnosed with ADHD. It is hypothesized that children receiving behavioral and (if necessary) pharmacologi...	Parents, researchers, and clinicians have long suspected that inadequate sleep in many children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) can exacerbate symptoms of hyperactivity and inattentiveness, leading to further cognitive and behavioral disruptions. Extant sleep studies report that upwards o...	Attention Deficit Hyperactivity Disorder	Attention Deficit Hyperactivity Disorder (ADHD)	null	2	arm 1: Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions. arm 2: Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.	[ 0, 0 ]	2	[ 5, 0 ]	intervention 1: A structured sleep protocol is taught to parents, use of a white noise generator intervention 2: Body Weight \<40mg will be given 3mg at bedtime for two weeks Body Weight \>40mg will be given 6 mg at bedtime for two weeks	intervention 1: Sleep Intervention intervention 2: Melatonin	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	8	NCT00867451	1COMPLETED	2011-07-01	2010-01-01	Children's Hospital Medical Center, Cincinnati	7OTHER	false	false	false	null	0
[ 5 ]	15	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	0ALL	false	This study will determine the effectiveness of antidepressant medication in preventing depression and improving recovery in people who have been supported by mechanical ventilators in an intensive care unit (ICU).	More than one third of all people admitted to ICUs in hospitals require mechanical ventilation for respiratory failure. Many people who survive after being on mechanical ventilation for a prolonged time have significant issues with recovery and quality of life when discharged from the ICU. They are also more prone to d...	Depression	Critical Illness Intensive Care Unit Acute Respiratory Failure Prolonged Mechanical Ventilation	null	2	arm 1: Participants will receive 8 weeks of escitalopram treatment. arm 2: Participants will receive 8 weeks of placebo pills.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents intervention 2: Placebo pills for 8 weeks	intervention 1: Escitalopram intervention 2: Placebo	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	15	NCT00872027	1COMPLETED	2011-07-01	2009-04-01	University of Minnesota	7OTHER	false	false	false	null	0
[ 4 ]	176	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye). The study consists of a double-masked phase, and open-labeled phase, and an open-labeled maintenance phase. For the first 3 months of the study, pat...	null	Atopic Conjunctivitis		null	2	arm 1: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day. arm 2: Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution ...	[ 0, 5 ]	2	[ 0, 0 ]	intervention 1: Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months. intervention 2: Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.	intervention 1: Cyclosporine Vehicle intervention 2: Cyclosporine 0.010%	12	Bakersfield \| California \| United States \| -119.01871 \| 35.37329 Randwick \| New South Wales \| Australia \| 151.24895 \| -33.91439 Ottawa \| Ontario \| Canada \| -75.69812 \| 45.41117 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804 Dijon \| Burgundy \| France \| 5.01667 \| 47.31667 Munich \| Bavaria \| Germany \| 11.57549 \| 48.13743 Ba...	258	NCT00884585	1COMPLETED	2011-07-01	2009-05-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 4 ]	310	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits will occur at 4 week intervals for 16 weeks with the ...	null	Pulmonary Hypertension		null	2	arm 1: Identical placebo tablets to UT-15C, doses were titrated in the same manner arm 2: Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: treprostinil diolamine sustained release tablets intervention 2: None	intervention 1: UT-15C SR intervention 2: Placebo	62	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Fresno \| California \| United States \| -119.77237 \| 36.74773 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Sacramento \| Cal...	310	NCT00887978	1COMPLETED	2011-07-01	2009-06-01	United Therapeutics	4INDUSTRY	false	false	false	null	0
[ 4 ]	557	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.	null	Overactive Bladder		null	2	arm 1: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). arm 2: Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botuli...	[ 0, 5 ]	2	[ 2, 0 ]	intervention 1: OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applic...	intervention 1: onabotulinumtoxinA intervention 2: normal saline	2	Newport Beach \| California \| United States \| -117.92895 \| 33.61891 Victoria \| British Columbia \| Canada \| -123.35155 \| 48.4359	550	NCT00910845	1COMPLETED	2011-07-01	2009-09-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	24	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	2MALE	false	The primary objective was to evaluate efficacy of a single dose of Liproca Depot in patients with localized prostate cancer. Primary efficacy variable was the proportion of patients showing PSA nadir. 24 Caucasian men, with a mean age at inclusion of 68.4 years, with localized prostate cancer were injected once with a ...	Patients with localized prostate cancer were followed to progression or maximum 24 weeks after a single injection in one lobe of 2-8 mL ready-made paste (corresponding to 400-1600 mg 2-Hydroxyflutamid). Progression was defined as an increase in PSA by \> 25% over baseline or on-treatment nadir.Among the 24 patients the...	Prostate Cancer	Prostate cancer	null	1	arm 1: Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe	[ 0 ]	2	[ 0, 0 ]	intervention 1: Ready made paste including 600 mg 2-HOF for injection as a single dose intervention 2: The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to adm...	intervention 1: 2-hydroxyflutamide (2-HOF) [Liproca Depot] intervention 2: 2-Hydroxyflutamide	2	Tampere \| N/A \| Finland \| 23.78712 \| 61.49911 Tampere \| N/A \| Finland \| 23.78712 \| 61.49911	24	NCT00913263	1COMPLETED	2011-07-01	2009-06-01	Lidds AB	4INDUSTRY	false	false	false	null	0
[ 3 ]	24	RANDOMIZED	CROSSOVER	0TREATMENT	0NONE	false	0ALL	true	To assess and compare the pharmacokinetics of Melphalan HCL for Injection (Propylene Glycol-Free) versus Alkeran for Injection in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).	This study will be a multicenter, open-label, randomized, comparative, cross-over study of high-dose Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection conducted in 24 patients who have symptomatic MM and qualify for ASCT. During the Study Period, patients will be randomized to receive 100mg...	Multiple Myeloma	autologous stem cell transplantation	null	2	arm 1: Subjects begin with treatment Melphalan and crossover to treatment Alkeran arm 2: Subjects begin with treatment Alkeran and crossover to treatment Melphalan.	[ 5, 5 ]	2	[ 0, 0 ]	intervention 1: Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT. intervention 2: Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propyl...	intervention 1: Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection intervention 2: Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)	1	Kansas City \| Kansas \| United States \| -94.62746 \| 39.11417	24	NCT00925782	1COMPLETED	2011-07-01	2010-01-01	Acrotech Biopharma Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	10	RANDOMIZED	PARALLEL	null	2DOUBLE	false	0ALL	true	We will prospectively study 2 groups of diabetic patients treated with pioglitazone or placebo for 26 weeks. Bone marrow aspirates will be obtained from these patients at baseline and after 26 weeks of treatment, and hBMCs will be isolated from these bone marrow aspirations. The ability of hBMCs to differentiate into o...	E2a. Screening: Prescreening of electronic medical records will be used as much as possible to reduce screen failure rates. Patients will undergo a full history (with special focus on inclusion and exclusion criteria), physical exam, and blood draw. Lab work will consist of CBC, PT, PTT, CMP, HbA1c, PTH, serum beta-HCG...	Osteoblast Adipocytes Bone Density Osteocalcin Adiponectin Mesenchymal Stem Cells	pioglitazone human bone marrow stem cells adipocytes osteoblasts bone mineral density adiponectin leptin CTX P1NP Osteocalcin	null	2	arm 1: half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician. arm 2: The other half will be randomized to placebo for 6 months. The pla...	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: 6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark. intervention 2: The placebo pills also start out with one ("15mg") pill qday and are increased to 2 tablets ("30m...	intervention 1: Pioglitazone intervention 2: Placebo	1	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749	10	NCT00927355	1COMPLETED	2011-07-01	2009-04-01	Emory University	7OTHER	false	false	false	null	0
[ 4 ]	427	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.	null	Type 2 Diabetes Mellitus	diabetes; exenatide once weekly; Byetta; glargine; Lantus; Amylin; Lilly	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: subcutaneous injection, 2.0mg, once a week; intervention 2: subcutaneous injection, titrated to achieve fasting serum glucose target, once a day	intervention 1: exenatide once weekly intervention 2: insulin glargine	22	Aomori \| N/A \| Japan \| 140.73333 \| 40.81667 Chiba \| N/A \| Japan \| 140.11667 \| 35.6 Ehime \| N/A \| Japan \| N/A \| N/A Fukuoka \| N/A \| Japan \| 130.41667 \| 33.6 Gunma \| N/A \| Japan \| N/A \| N/A Hiroshima \| N/A \| Japan \| 132.45 \| 34.4 Hokkaido \| N/A \| Japan \| N/A \| N/A Hyōgo \| N/A \| Japan \| 144.43333 \| 43.36667 Ibaraki \| N/A ...	427	NCT00935532	1COMPLETED	2011-07-01	2009-07-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 0 ]	32	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.	A quadrivalent human papilloma virus (HPV) vaccine called Gardasil had recently (at start of study) been developed and approved by the FDA for the prevention of cervical HPV infection and cervical cancer, which is associated with infection from this virus. It is unknown whether the same vaccine could also be of benefit...	HIV Positive Anal Condylomata Anal Warts HIV Infections	HIV HPV Anal condylomata Vaccine HIV positive patients Anal condylomata or anal warts	null	2	arm 1: Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment. arm 2: The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at tw...	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: 0.5 ml intervention 2: 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.	intervention 1: Saline intervention 2: Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	0	NCT00941889	1COMPLETED	2011-07-01	2007-07-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 5 ]	103	RANDOMIZED	CROSSOVER	0TREATMENT	3TRIPLE	false	0ALL	true	1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of Cervical dystonia. 2. double blind, randomised, multi center, crossover study	1. Prospective, randomized, head-to-head, double-blind, cross-over study. 2. Total patients: A group 51, B group 51 3. Study duration: 16 + 4 + 16 weeks. Eligible patients will be randomised at baseline to receive either Dysport® or Botox® and monitored at weeks 2, 4, 8, 12, 16 weeks. After 4 weeks of wash out period, ...	Cervical Dystonia	cervical dystonia botulinum toxin	null	2	arm 1: Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA) arm 2: Botox® injection in first intervention period and Dysport® in second intervention period (after washout peri...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units intervention 2: Cross over injection of Dysport® (\<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units	intervention 1: Dysport® (abobotulinumtoxinA) intervention 2: Botox® (onabotulinumtoxinA)	7	Seongnam-si \| Gyeonggi-do \| South Korea \| 127.13778 \| 37.43861 Busan \| N/A \| South Korea \| 129.03004 \| 35.10168 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Korea \| 126.9784 \| 37.566 Seoul \| N/A \| South Kore...	188	NCT00950664	1COMPLETED	2011-07-01	2009-08-01	Seoul National University Hospital	7OTHER	false	false	false	null	0
[ 4 ]	145	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will test the effectiveness of warfarin in patients with IPF. Approximately 256 patients will be randomized 1:1 to either warfarin or placebo. Patients will return at week 1 for a safety review and every 16 weeks for 48 weeks. The primary endpoint in the study is the time to either death, non-bleeding/non-el...	Study design: ACE-IPF was a double-blind, randomized, placebo-controlled trial of an oral warfarin dose adjusted to an international normalized ratio (INR) response of 2.0 to 3.0, compared with a sham dose-adjusted placebo. The trial was originally designed as an event-driven study with a treatment period of up to 144...	Idiopathic Pulmonary Fibrosis	IPF Warfarin	null	2	arm 1: Oral warfarin titrated to an international normalization ratio (INR) of 2-3 arm 2: Oral placebo (1mg or 2.5mg)	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3. intervention 2: Oral placebo (1mg or 2.5mg)	intervention 1: warfarin intervention 2: placebo	22	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Denver \| Colorado \| United States \| -104.9847 \| 39.73915 New Haven \| Connecticut \| United States \| -72.92816 \| 41.30815 Miami \| ...	145	NCT00957242	6TERMINATED	2011-07-01	2009-10-01	Duke University	7OTHER	false	false	false	null	0
[ 0 ]	7	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.	Hypothesis: Rosuvastatin therapy will improve mortality and reduce the need for mechanical ventilation in patients experiencing respiratory distress as a complication of influenza.	Acute Respiratory Distress Syndrome Influenza H1N1 Influenza	ARDS H1N1 Influenza Statin	null	2	arm 1: Placebo arm 2: Experimental arm	[ 2, 0 ]	2	[ 0, 0 ]	intervention 1: 20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge intervention 2: Placebo tablet identical to active therapy. 1 tablet per day	intervention 1: Rosuvastatin (crestor) intervention 2: Placebo	21	Little Rock \| Alaska \| United States \| N/A \| N/A Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Stanford \| California \| United States \| -122.16608 \| 37.42411 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Iowa City \| Iowa \| United States \| -91.53017 \| 41.66113 Baltiomore \| Maryland \| United States...	7	NCT00970606	6TERMINATED	2011-07-01	2009-10-01	Gordon Bernard	7OTHER	false	false	false	null	0
[ 5 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to assess the effect of treatment with Advair Diskus on depression using the Cornell depression scale in COPD patients in the nursing home.	We are studying 35 residents in the ECF with a diagnosis of COPD. We are evaluating them for depressive symptoms using the Cornell Depression Scale and the MDS 3.0 section D. We are selecting patients who are not currently on treatment with Advair and starting them on Advair Diskus50/250 1 inhalation bid for a period o...	Chronic Obstructive Pulmonary Disease Depression	COPD Depression Nursing Home	null	1	arm 1: open label treatment with Advair diskus in COPD patients	[ 0 ]	1	[ 0 ]	intervention 1: Advair diskus 50/250 1 inhalation bid for 16 weeks	intervention 1: Advair diskus	2	Brooksville \| Florida \| United States \| -82.38991 \| 28.55554 Centerville \| Ohio \| United States \| -84.15938 \| 39.62839	27	NCT00974246	1COMPLETED	2011-07-01	2009-10-01	Valley Medical Research	7OTHER	false	false	false	null	0
[ 3 ]	29	RANDOMIZED	PARALLEL	7BASIC_SCIENCE	4QUADRUPLE	false	0ALL	false	To explore the effect of CP-690,550 on blood and synovial markers in subjects with rheumatoid arthritis. To evaluate the safety, tolerability and efficacy of CP-690,550.	null	Rheumatoid Arthritis		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week intervention 2: Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week	intervention 1: CP-690,550 + methotrexate intervention 2: Placebo + Methotrexate	15	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Frederick \| Maryland \| United States \| -77.41054 \| 39.41427 Battle Creek \| Mich...	29	NCT00976599	1COMPLETED	2011-07-01	2009-11-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	20	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Attention Deficit Hyperactivity Disorder (ADHD) is a neurobiological disorder characterized by lifelong issues of inattention, distraction, organizational difficulties, forgetfulness, restlessness, talking out of turn, difficulty waiting and interrupting others. ADHD is the second most common neuropsychiatric disorder ...	This will be a 12-week study of twenty enrolled participants with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV) criteria adult ADHD (age 18-55), with a goal of completing twenty participants in the trial. The primary objective of this study is to determine the effect of droxidopa th...	Attention Deficit Hyperactivity Disorder	Attention Deficit Hyperactivity Disorder ADHD Adult ADHD Adult Attention Deficit Hyperactivity Disorder	null	2	arm 1: 3 weeks of open label droxidopa (200, 400, or 600 milligrams \[mg\] three times daily \[TID\]) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25 mg or 50 mg TID). arm 2: 2 week double-blind period in which participants either continued to receive droxidopa+carbidopa treatment or plac...	[ 0, 2 ]	1	[ 0 ]	intervention 1: 3 weeks of open label droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) monotherapy followed by 3 weeks of droxidopa in combination with carbidopa (25mg or 50mg TID) followed by 2 weeks of double blind continued droxidopa+carbidopa or placebo	intervention 1: Droxidopa+Carbidopa	1	New York \| New York \| United States \| -74.00597 \| 40.71427	31	NCT00983814	1COMPLETED	2011-07-01	2009-10-01	Chelsea Therapeutics	4INDUSTRY	false	false	false	null	0
[ 0 ]	5	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying how well metformin hydrochloride works in treating women with stage I or stage II breast cancer that can be removed by surgery.	OBJECTIVES: Primary * To determine the in situ effects of metformin hydrochloride on proliferation (Ki67) and apoptosis (caspase-3) in women with operable stage I or II breast cancer. Secondary * To determine the in situ biologic effect of metformin hydrochloride on the AMP kinase, MTOR/PI3K, and IGF pathways in br...	Breast Cancer	stage I breast cancer stage II breast cancer	null	1	arm 1: Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery	[ 0 ]	2	[ 0, 10 ]	intervention 1: Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery intervention 2: Blood and tissue collection to determine the in situ biologic effect of metformin	intervention 1: metformin hydrochloride intervention 2: laboratory biomarker analysis	3	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	5	NCT00984490	6TERMINATED	2011-07-01	2009-09-01	Vanderbilt-Ingram Cancer Center	7OTHER	false	false	false	null	0
[ 4 ]	86	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.	HZT-501, a fixed-dose combination of ibuprofen, a pain and inflammation relieving non-steroidal anti-inflammatory drug (NSAID), and famotidine, a histamine type 2 receptor antagonist (H2RA), is being developed for the treatment of patients with signs and symptoms of osteoarthritis, rheumatoid arthritis, mild to moderat...	Osteoarthritis Rheumatoid Arthritis Chronic Low Back Pain Chronic Regional Pain Syndrome Chronic Soft Tissue Pain	NSAID Chronic Pain Osteoarthritis Rheumatoid Arthritis	null	1	arm 1: Open-label treatment with HZT-501	[ 0 ]	1	[ 0 ]	intervention 1: Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day	intervention 1: HZT-501	4	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Morton Grove \| Illinois \| United States \| -87.78256 \| 42.04059 Duncansville \| Pennsylvania \| United States \| -78.4339 \| 40.42341 Dallas \| Texas \| United States \| -96.80667 \| 32.78306	86	NCT00984815	1COMPLETED	2011-07-01	2009-09-01	Amgen	4INDUSTRY	false	false	false	null	0
[ 5 ]	263	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional HumaPen Luxura without memory function.	null	Diabetes Mellitus, Type 1		null	2	arm 1: Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks arm 2: Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks	[ 0, 0 ]	4	[ 0, 0, 1, 1 ]	intervention 1: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks intervention 2: subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks intervention 3: subcutaneously, daily for 24 weeks intervention 4: subcutaneously, daily for 24 weeks	intervention 1: Insulin Lispro intervention 2: Huminsulin Regular intervention 3: HumaPen Memoir intervention 4: HumaPen Luxura	29	Aschaffenburg \| N/A \| Germany \| 9.15214 \| 49.97704 Aßlar \| N/A \| Germany \| 8.46273 \| 50.59163 Bad Mergentheim \| N/A \| Germany \| 9.77361 \| 49.4925 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Bosenheim \| N/A \| Germany \| 7.91382 \| 49.84472 Diez \| N/A \| Germany \| 8.00735 \| 50.37419 Dresden \| N/A \| Germany \| 13.73832 \| 51....	261	NCT00985712	1COMPLETED	2011-07-01	2009-10-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	20	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Some patients who need kidney transplants have high levels of antibodies that make them incompatible with most potential deceased donor kidney offers. These patients are considered highly-sensitized and are very difficult to transplant because the likelihood that they will receive a compatible organ is very low. There ...	null	Kidney Failure		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening...	intervention 1: IVIg and rituximab	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	0	NCT00986947	6TERMINATED	2011-07-01	2009-09-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 3 ]	46	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	2MALE	true	The purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of sperm).	This is an open-label (all people know the identity of the intervention), multicenter trial (conducted in more than one center) in participants with metastatic castrate-resistant prostate cancer. The trial consists of 3 phases: screening period, treatment period of approximately 4 months, and a follow-up period (Week 1...	Prostate Cancer	Prostate cancer Infusion Carlumab CNTO 888	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.	intervention 1: Carlumab	13	Orange City \| Florida \| United States \| -81.29867 \| 28.94888 Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756 Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632 Antwerp \| N/A \| Belgium \| 4.40026 \| 51.22047 Brussels \| N/A \| Belgium \| 4.34878 \| 50.85045 Wilrijk \| N/A \| Belgium \| 4.39513 \| 51.16...	46	NCT00992186	1COMPLETED	2011-07-01	2009-09-01	Centocor Research & Development, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	464	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.	null	Multiple Sclerosis		null	4	arm 1: ACT-128800 Dose 1 arm 2: ACT-128800 Dose 2 arm 3: ACT-128800 Dose 3 arm 4: Matching placebo	[ 0, 0, 0, 2 ]	4	[ 0, 0, 0, 0 ]	intervention 1: ACT-128800 (Dose 1) administered orally once daily intervention 2: Matching placebo administered orally once daily intervention 3: ACT-128800 (Dose 2) administered orally once daily intervention 4: ACT-128800 (Dose 3) administered orally once daily	intervention 1: ACT-128800 Dose 1 intervention 2: Placebo intervention 3: ACT-128800 Dose 2 intervention 4: ACT-128800 Dose 3	115	Scottsdale \| Arizona \| United States \| -111.89903 \| 33.50921 Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Sacramento \| California \| United States \| -121.4944 \| 38.58157 Stanford \| California \| United States \| -122.16608 \| 37.42411 Sarasota \| Florida \| United States \| -82.53065 \| 27.33643 Indianapolis \| Indi...	462	NCT01006265	1COMPLETED	2011-07-01	2009-10-01	Actelion	4INDUSTRY	false	false	false	null	0
[ 4 ]	322	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.	In this study, 220 patients will be divided into two groups randomly (by chance), like flipping a coin. Each group will receive a different treatment. The results for each group are compared to each other. There are 2 treatment groups in this study, Group 1 and Group 2. Group 1 will receive placebo at Weeks 0 and 4, us...	Psoriasis	psoriasis asian patients Chinese ustekinumab CNTO 1275 Stelara	null	2	arm 1: placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16 arm 2: placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Subcutaneous injection at Week 0 and 4 intervention 2: 45 mg subcutaneous injection at Week 12 and 16 intervention 3: Subcutaneous injection at Week 12 intervention 4: 45 mg subcutaneous injection at Week 0, 4 and 16	intervention 1: placebo intervention 2: ustekinumab intervention 3: placebo intervention 4: ustekinumab	9	Beijing \| N/A \| China \| 116.39723 \| 39.9075 Chongqing \| N/A \| China \| 106.55771 \| 29.56026 Dalian \| N/A \| China \| 121.60222 \| 38.91222 Guangzhou \| N/A \| China \| 113.25 \| 23.11667 Hangzhou \| N/A \| China \| 120.16142 \| 30.29365 Nanjing \| N/A \| China \| 118.77778 \| 32.06167 Shanghai \| N/A \| China \| 121.45806 \| 31.22222 Shen...	638	NCT01008995	1COMPLETED	2011-07-01	2009-10-01	Centocor, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).	This study is a single-site, randomized, double-blind, two group trial assessing the PK, safety and efficacy of WR 279,396 Topical Cream and Paromomycin Topical Cream in subjects with CL. Subjects will be screened over a period up to 28 days for eligibility including parasitology for confirmation of ulcerative CL. Subj...	Leishmaniasis, Cutaneous	leishmaniasis cutaneous WR 279,396 paromomycin gentamicin pharmacokinetics safety efficacy	null	2	arm 1: None arm 2: None	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: topical application to CL lesions once daily for 20 days intervention 2: topical application to CL lesions once daily for 20 days	intervention 1: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) intervention 2: Paromomycin Alone Cream (15% paromomycin topical cream)	1	Lima \| N/A \| Peru \| -77.02824 \| -12.04318	30	NCT01032382	1COMPLETED	2011-07-01	2010-01-01	U.S. Army Medical Research and Development Command	1FED	false	false	false	null	0
[ 0 ]	160	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	false	The purpose of this study is to compare different medication combinations used in a periarticular injection after total knee replacement surgery(TKR). A periarticular injection is an injection that is given into the tissues surrounding the knee joint. The injection is given while the patient is still in surgery. The s...	Data Collection: Data will be collected from the patient's pre-operative office visit, up to six weeks post-operatively. Variables Pre-operative Collection: * Vital signs * Hb/Hct * Age * Sex * BMI * WOMAC Score - Screen Failure at 36 or 12 * Visual Analog Scale (VAS) Intra-operative Collection: * Duration of sur...	Osteoarthritis,Knee	Analgesia postoperative pain periarticular arthroplasty pain management	null	4	arm 1: Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml) arm 2: Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) arm 3: Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml) ...	[ 1, 1, 1, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Ropivacaine 5mg/ml (49.25 ml) intervention 2: Toradol 30mg/ml (1 ml) intervention 3: Clonidine 0.1 mg/ml (0.08mg - 0.8 ml) intervention 4: Epinephrine 1 mg/ml (0.5 ml)	intervention 1: Ropivacaine intervention 2: Toradol intervention 3: Clonidine intervention 4: Epinephrine	0	null	160	NCT01042093	1COMPLETED	2011-07-01	2010-01-01	Towson Orthopaedic Associates	7OTHER	false	false	false	null	0
[ 4 ]	251	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one inhalation b.i.d, or standard COPD therapy. Standard (reference) COPD treatment arm should be the group to refer to when safety results of formoterol arm will be evaluated. 240 patients with moderate-to-severe COPD will be rand...	null	Chronic Obstructive Pulmonary Disease	Chronic Obstructive Pulmonary Disease COPD Japanese Phase 3 Safety OT Oxis	null	1	arm 1: Formoterol 9 μg/dose	[ 0 ]	1	[ 0 ]	intervention 1: 9 μg/dose, Inhaled, twice daily for 52 weeks	intervention 1: Formoterol (OT)	27	Nagoya \| Aichi-ken \| Japan \| 136.90641 \| 35.18147 Akita \| Akita \| Japan \| 140.11667 \| 39.71667 Fukuoka \| Fukuoka \| Japan \| 130.41667 \| 33.6 Chitose \| Hokkaido \| Japan \| 141.65222 \| 42.81944 Obihiro \| Hokkaido \| Japan \| 143.20444 \| 42.91722 Sapporo \| Hokkaido \| Japan \| 141.35 \| 43.06667 Ako \| Hyōgo \| Japan \| 134.37035 \|...	251	NCT01047553	1COMPLETED	2011-07-01	2009-12-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 4 ]	229	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.	null	Hypertriglyceridemia	hypertriglyceridemia omega-3 fatty acids statin triglycerides lipids EPA docosahexaenoic acid fish fatty acids fibrates niacin lipid atorvastatin Lovaza simvastatin lovastatin pravastatin fluvastatin rosuvastatin Trilipix Vytorin Simcor ezetimibe Zetia ethyl-EPA ethyl icosapentate Crestor Zocor Lipitor Niaspan LDL HDL ...	null	3	arm 1: None arm 2: None arm 3: None	[ 2, 0, 0 ]	3	[ 0, 0, 0 ]	intervention 1: AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12) intervention 2: AMR101 (ethyl icosapentate) 2 capsules/day with placebo 2 capsules/day for 12 weeks (Weeks 1-12) intervention 3: Placebo 4 capsules/day for 12 weeks (Weeks 1-12)	intervention 1: AMR101 (ethyl icosapentate) - 4 g/day intervention 2: AMR101 (ethyl icosapentate) - 2 g/day intervention 3: Placebo	60	Sacramento \| California \| United States \| -121.4944 \| 38.58157 Golden \| Colorado \| United States \| -105.2211 \| 39.75554 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Miami \| Florida \| United States \| -80.19366 \| 25.77427 Ocala \| Florida \| United States \| -82.14009 \| 29.1872 Addison \| Illinois \| United States \|...	229	NCT01047683	1COMPLETED	2011-07-01	2009-12-01	Amarin Pharma Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	244	null	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events (side effects) associated to these drugs.	This is a study to find out what the effects are of long-term use of atypical antipsychotics (drugs used to treat mental health and some behavior disorders) in children and adolescents on their growth and physical maturity. Atypical antipsychotics are used in the treatment of a wide range of disorders in children and a...	Schizophrenia Bipolar Disorder Autistic Disorder Conduct and Other Disruptive Behavior Disorders	Schizophrenia Bipolar Disorder Autistic Disorder Conduct and Other Disruptive Behavior Disorders Risperidone RISPERDAL Antipsychotic Agents Prolactin Pediatrics	null	2	arm 1: Risperidone as per local prescribing practices arm 2: Other atypical antipsychotic drugs as per local prescribing practices	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: As per local prescribing practices intervention 2: As per local prescribing practices	intervention 1: Risperidone intervention 2: Other atypical antipsychotic drugs	28	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Aurora \| Colorado \| United States \| -104.83192 \| 39.72943 Altamonte Springs \| Florida \| United States \| -81.36562 \| 28.66111 Gainesville \| Florida \| United States \| -82.32483 \| 29.65163 Smyrna \| Georgia \| United States \| -84.51438 \| 33.88399 Naperville ...	184	NCT01050582	1COMPLETED	2011-07-01	2009-10-01	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	4INDUSTRY	false	false	false	null	0
[ 4 ]	323	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine monotherapy versus placebo for the treatment of acute manic or mixed episodes associated with bipolar I disorder.	null	Bipolar Disorder Mania	Acute Mania Bipolar I Disorder	null	2	arm 1: Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks. arm 2: Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine. intervention 2: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.	intervention 1: Cariprazine intervention 2: Placebo	28	Long Beach \| California \| United States \| -118.18923 \| 33.76696 Riverside \| California \| United States \| -117.39616 \| 33.95335 San Diego \| California \| United States \| -117.16472 \| 32.71571 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Lake Charles \| Louisiana \| United States \| -93.2044 \| 30.21309 Flowood \|...	312	NCT01058096	1COMPLETED	2011-07-01	2010-02-01	Forest Laboratories	4INDUSTRY	false	false	false	null	0
[ 3 ]	30	NON_RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The objectives of the study are to evaluate the pharmacokinetics (PK), safety, and efficacy of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Topical Cream in subjects with cutaneous leishmaniasis (CL).	This study is a single-site, randomized, double-blind, two group trial assessing the PK, safety and efficacy of WR 279,396 Topical Cream and Paromomycin Topical Cream in subjects with CL. Subjects will be screened over a period up to 28 days for eligibility including parasitology for confirmation of ulcerative CL. Subj...	Leishmaniasis, Cutaneous	leishmaniasis cutaneous WR 279,396 paromomycin gentamicin pharmacokinetics safety efficacy	null	2	arm 1: Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days arm 2: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: topical application to CL lesions once daily for 20 days intervention 2: topical application to CL lesions once daily for 20 days	intervention 1: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream) intervention 2: Paromomycin Alone Cream (15% paromomycin topical cream)	1	Panama City \| N/A \| Panama \| -79.51973 \| 8.9936	30	NCT01083576	1COMPLETED	2011-07-01	2010-03-01	U.S. Army Medical Research and Development Command	1FED	false	false	false	null	0
[ 4 ]	86	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression	null	Non-infectious Uveitis	Quiescent uveitis intermediate uveitis panuveitis posterior uveitis uveitis NVS Definition: Words or phrases that best describe the protocol. Keywords help users find studies in the database. Avoid acronyms, abbreviations and trade names. Examples: Heart failure, aliskiren, heart attack, cardiovascular diseases Psorias...	null	4	arm 1: AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks arm 2: AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly arm 3: AIN457 150 mg s.c. and placebo s.c. at Baseline and Wee...	[ 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake intervention 2: Matching placebo to AIN457	intervention 1: AIN457 intervention 2: Placebo	35	Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Louisville \| Kentucky \| United States \| -85.75941 \| 38.25424 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Cambridge \| Massachusetts \| United States \| -71.10561 \| 42.3751 Teaneck \| New...	124	NCT01090310	6TERMINATED	2011-07-01	2010-08-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 3 ]	10	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	false	This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during right heart catheterization (RHC) in participants with pulmonary arterial hypertension (PAH). All participants will receive inhaled nitric oxide in oxygen or nitric ...	TREATMENT/FOLLOW-UP: Participants meeting eligibility criteria will receive open label nitric oxide at 80 ppm via a nasal cannula. Hemodynamic clinical laboratory and clinical assessment data will be collected at baseline, after 15 minutes of inhaled nitric oxide administration, post RHC procedure and at hospital disc...	Pulmonary Arterial Hypertension	Diagnostic Techniques and Procedures	null	1	arm 1: Nitric Oxide via GeNO Nitrosyl system	[ 0 ]	1	[ 0 ]	intervention 1: single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.	intervention 1: Nitric Oxide generated by the GeNO nitrosyl delivery system	3	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Dallas \| Texas \| United States \| -96.80667 \| 32.78306	0	NCT01092559	1COMPLETED	2011-07-01	2010-10-01	Geno LLC	4INDUSTRY	false	false	false	null	0
[ 0 ]	61	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise	The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in HbA1c compared to colesevelam HCl treatment by 1. improving the effects of colesevelam on fasting glucose metabolism 2. improving the effects of colsevelam on postprandial glucose metabolism	Diabetes Mellitus, Type 2	Colesevelam type 2 diabetes sitagliptin glucose metabolism	null	2	arm 1: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. arm 2: Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. Sita...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks. intervention 2: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.	intervention 1: Colesevelam HCl intervention 2: Sitagliptin	3	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Miami \| Florida \| United States \| -80.19366 \| 25.77427 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412	61	NCT01092663	1COMPLETED	2011-07-01	2010-03-01	KineMed	4INDUSTRY	false	false	false	null	0
[ 4 ]	40	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	true	0ALL	false	The purpose of this study is to investigate the utility of post-session administration of D-cycloserine to enhance fear extinction in a sample of people with acrophobia who will be treated with CBT.	null	Phobic Disorders	Phobias Anxiety Disorders D-Cycloserine Phobic Disorders Mental Disorders Heights Acrophobia	null	2	arm 1: Participants will receive placebo augmented cognitive behavioral therapy arm 2: Participants will receive D-Cycloserine augmented cognitive behavioral therapy	[ 2, 0 ]	3	[ 5, 0, 0 ]	intervention 1: The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT. intervention 2: D-Cycloserine intervention 3: Sugar Pill	intervention 1: Individual Cognitive Behavioral Therapy (CBT) intervention 2: D-Cycloserine intervention 3: Placebo	1	Dallas \| Texas \| United States \| -96.80667 \| 32.78306	58	NCT01102803	1COMPLETED	2011-07-01	2010-04-01	Southern Methodist University	7OTHER	false	false	false	null	0
[ 5 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The objectives of this study would be to see if the addition of vitamin D to fluticasone propionate provides greater symptomatic relief in patients with seasonal allergic rhinitis compared to fluticasone propionate treatment alone.	null	Seasonal Allergic Rhinitis		null	2	arm 1: Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season arm 2: Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season	[ 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 4000 IU once daily intervention 2: Placebo taken once daily intervention 3: 200 mcg daily, intranasal	intervention 1: Vitamin D3 intervention 2: Placebo intervention 3: Fluticasone Propionate	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	35	NCT01103934	1COMPLETED	2011-07-01	2010-06-01	University of Chicago	7OTHER	false	false	false	null	0
[ 5 ]	33	RANDOMIZED	CROSSOVER	null	0NONE	true	0ALL	false	The purpose of this study is to determine the pharmacogenetics, pharmacokinetics, and drug-drug interactions of sitagliptin therapy.	null	Healthy	Healthy volunteers	null	3	arm 1: ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses arm 2: ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses arm 3: ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: sitagliptin 100 mg x 1 dose intervention 2: atorvastatin 40 mg x 5 doses	intervention 1: Sitagliptin intervention 2: atorvastatin	1	Aurora \| Colorado \| United States \| -104.83192 \| 39.72943	33	NCT01112670	1COMPLETED	2011-07-01	2009-11-01	University of Colorado, Denver	7OTHER	false	false	false	null	0
[ 3 ]	63	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.	null	Psoriasis Vulgaris	Psoriasis Vulgaris Systemic Anti-psoriatic	null	4	arm 1: LEO 22811 0.5 mg: Oral solution arm 2: LEO 22811 1.5 mg: Oral solution arm 3: LEO 22811 3.0 mg: Oral solution arm 4: Placebo: Oral solution	[ 1, 1, 1, 2 ]	2	[ 0, 0 ]	intervention 1: Oral solution intervention 2: Placebo	intervention 1: LEO 22811 intervention 2: Placebo	2	Québec \| N/A \| Canada \| -71.21454 \| 46.81228 Paris \| N/A \| France \| 2.3488 \| 48.85341	63	NCT01116895	1COMPLETED	2011-07-01	2010-05-01	LEO Pharma	4INDUSTRY	false	false	false	null	0
[ 4 ]	128	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema. A subgroup of patients with Proliferative Diabetic Retinopathy were included to evaluate the efficac...	null	Visual Impairment Due to Diabetic Macular Edema	Diabetic macular edema DME Proliferative diabetic retinopathy PDR ranibizumab laser	null	2	arm 1: Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment. arm 2: Active laser tre...	[ 0, 1 ]	3	[ 3, 0, 0 ]	intervention 1: Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment. intervention 2: Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment. inter...	intervention 1: Active laser photocoagulation intervention 2: Sham injections intervention 3: Ranibizumab 0.5 mg	34	Aschaffenburg \| N/A \| Germany \| 9.15214 \| 49.97704 Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Bonn \| N/A \| Germany \| 7.09549 \| 50.73438 Bremen \| N/A \| Germany \| 8.80717 \| 53.07582 Chemnitz \| N/A \| Germany \| 12.92922 \| 50.8357 Cologne \| N/A \| Germany \| 6.95 \| 50.93333 Darmstadt \| N/A \| Germany \| 8.65027 \| 49.87167 Des...	128	NCT01131585	6TERMINATED	2011-07-01	2010-06-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 4 ]	810	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week...	null	Asthma	Salmeterol fluticasone furoate Vilanterol fluticasone propionate GW642444	null	2	arm 1: Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks arm 2: Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks	[ 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks intervention 2: Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks intervention 3: Inhalation powder inhaled orally once daily for 24 weeks intervention 4: Inhalation powder i...	intervention 1: Fluticasone furoate/Vilanterol Inhalation Powder intervention 2: Fluticasone propionate/salmeterol Inhalation Powder intervention 3: Placebo (1) intervention 4: Placebo (2)	63	Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Riverside \| California \| United States \| -117.39616 \| 33.95335 Rolling Hills Estates \| California \| United States \| -118....	806	NCT01147848	1COMPLETED	2011-07-01	2010-06-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 3 ]	71	RANDOMIZED	PARALLEL	7BASIC_SCIENCE	2DOUBLE	false	0ALL	false	The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.	null	Chronic Obstructive Pulmonary Disease Lung Disease	Respiratory disease chronic obstructive pulmonary disease	null	2	arm 1: Oral treatment arm 2: Oral treatment	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 100mg Oral dose od intervention 2: Oral dose od	intervention 1: AZD2423 intervention 2: AZD2423 Placebo	1	Hanover \| Hannover \| Germany \| 9.73322 \| 52.37052	44	NCT01153321	1COMPLETED	2011-07-01	2010-10-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3 ]	169	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	null	The purpose of this study was to determine whether, in patients with mild to moderate knee osteoarthritis, canakinumab is safe and tolerable when injected intra-articularly.	This is a randomized, double-blind, parallel group, placebo controlled 18 weeks study, consisting of two parts: 1. Part A: an ascending single dose part in which the safety and tolerability of up to 4 different canakinumab doses are studied (starting dose 150 mg, maximum dose 600 mg). 2. Part B: a double-dummy, active...	Osteoarthritis	Osteo arthritis pain control intra- articular injections Knee OA	null	5	arm 1: In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg. arm 2: Participants received a single intra-articular injection of canakinumab-matching placebo. arm 3: Participants received a si...	[ 0, 2, 0, 2, 1 ]	4	[ 2, 0, 0, 0 ]	intervention 1: Intra-articular injection intervention 2: Intra-articular injection intervention 3: Tablets for oral administration intervention 4: Tablets for oral administration	intervention 1: Canakinumab intervention 2: Placebo to canakinumab intervention 3: Naproxen intervention 4: Placebo to Naproxen	13	Anniston \| Alabama \| United States \| -85.83163 \| 33.65983 Mesa \| Arizona \| United States \| -111.82264 \| 33.42227 San Diego \| California \| United States \| -117.16472 \| 32.71571 Westlake Village \| California \| United States \| -118.80565 \| 34.14584 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Topeka \| Kansas ...	169	NCT01160822	1COMPLETED	2011-07-01	2010-04-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 3 ]	356	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.	null	Dry Eye Syndrome		null	6	arm 1: 0.3% BOL-303242-X ophthalmic suspension arm 2: 2% BOL-303242-X ophthalmic suspension arm 3: Vehicle twice daily (BID) arm 4: 1% BOL-303242-X ophthalmic suspension arm 5: 2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM) arm 6: Vehicle in the AM and 2% BOL-303242-X ophtha...	[ 0, 0, 2, 0, 0, 0 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks. intervention 2: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks. intervention 3: Placebo Comparator: Vehicle BID for 12 weeks. intervention 4: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks. intervention 5: 2% BOL-303242-X ophthalm...	intervention 1: 0.3% BOL-303242-X ophthalmic suspension intervention 2: 2% BOL-303242-X ophthalmic suspension intervention 3: Placebo Comparator: Vehicle intervention 4: 1% BOL-303242-X ophthalmic suspension intervention 5: 2% BOL-303242-X ophthalmic suspension AM intervention 6: 2% BOL-303242-X ophthalmic suspension P...	1	Rochester \| New York \| United States \| -77.61556 \| 43.15478	351	NCT01163643	1COMPLETED	2011-07-01	2010-07-01	Bausch & Lomb Incorporated	4INDUSTRY	false	false	false	null	-0
[ 3 ]	43	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.	null	Plaque Psoriasis		null	2	arm 1: Subjects randomized to receive lotion arm 2: Subjects randomized to receive cream	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Apply 3.5 grams twice daily for 1-2 weeks intervention 2: Apply 3.5 grams twice daily for 1-2 weeks	intervention 1: Halobetasol Proprionate Lotion 0.05% intervention 2: Halobetasol Proprionate Cream 0.05%	5	San Diego \| California \| United States \| -117.16472 \| 32.71571 Clinton Township \| Michigan \| United States \| -82.91992 \| 42.58698 Troy \| Michigan \| United States \| -83.14993 \| 42.60559 Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709 Austin \| Texas \| United States \| -97.74306 \| 30.26715	43	NCT01166646	1COMPLETED	2011-07-01	2010-07-01	Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	136	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	true	0ALL	false	A major limitation to the widespread acceptance of colonoscopy as a procedure to screen for colorectal cancer is the laxative preparation. Phosphate-based preps (e.g. Fleets Phosphosoda) are now used on a limited basis because of their known association with renal injury. Polyethylene glycol (PEG) mixed with a balanced...	Objective To determine whether Miralax is as efficacious for bowel cleansing as standard Golytely for screening colonoscopy. This study is designed and powered to be an non-inferiority study. Primary aim: To compare the quality of bowel preparation between Miralax and Golytely Secondary Aims: * compare patient comfo...	Colon Cancer	PEG-3350, polyethylene glycol, colonoscopy	null	2	arm 1: 255 miralax with 64 oz gatorade. arm 2: Golytely 4 Liters	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation. intervention 2: Golytely 4 liters	intervention 1: PEG-3350 and Gatorade intervention 2: Golytely 4 liters	1	Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	136	NCT01170754	1COMPLETED	2011-07-01	2010-04-01	Temple University	7OTHER	false	false	false	null	0
[ 0 ]	3	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	true	0ALL	false	This will be a randomized two arm prospective study to evaluate postoperative ureteral stent pain. One arm will be given 3 days of preoperative darifenacin and the control group will have the standard of care which is no preoperative anticholinergic medication. The primary endpoints will be decreased pain scores and le...	The purpose of the study is to determine if preoperative dosing of darifenacin will assist in postoperative ureteral stent pain. This will be a randomized two arm prospective study to evaluate postoperative ureteral stent pain. One arm will be given 3 days of preoperative darifenacin and the control group will have the...	Overactive Bladder Renal Colic Pain, Postoperative	Stents [E07.695.750] Darifenacin (C101207) Kidney calculi	null	2	arm 1: 3 days of preoperative darifenacin anticholinergic medication arm 2: The control group will have the standard of care which is no preoperative anticholinegic medication.	[ 1, 4 ]	1	[ 0 ]	intervention 1: an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be f...	intervention 1: Darifenacin	1	Columbia \| Missouri \| United States \| -92.33407 \| 38.95171	0	NCT01189071	6TERMINATED	2011-07-01	2009-08-01	University of Missouri-Columbia	7OTHER	false	false	false	null	0
[ 4 ]	446	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).	null	Lateral Canthus Rhytides Crow's Feet Lines		null	2	arm 1: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1. arm 2: normal saline injected into bilateral Crow's Feet Line areas on Day 1.	[ 0, 2 ]	2	[ 2, 0 ]	intervention 1: 24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1 intervention 2: Injected into bilateral Crow's Feet Line areas on Day 1	intervention 1: onabotulinumtoxinA intervention 2: normal saline	4	Newport Beach \| California \| United States \| -117.92895 \| 33.61891 Aalst \| N/A \| Belgium \| 4.0355 \| 50.93604 Vancouver \| British Columbia \| Canada \| -123.11934 \| 49.24966 Sutton Coldfield \| England \| United Kingdom \| -1.81667 \| 52.56667	444	NCT01189747	1COMPLETED	2011-07-01	2010-10-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 2 ]	16	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with carboplatin and paclitaxel, and to assess the pharmacokinetics of CS-7017 in combination with carboplatin and paclitaxel.	null	Carcinoma, Non-Small-Cell Lung	PPAR gamma agonist Tumor Cancer Antineoplastic Agent Respiratory Tract Neoplasms Carboplatin Paclitaxel Neoplasms	null	1	arm 1: Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks) Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks) Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles (1...	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: Drug: CS-7017 from 0.25 mg BID to 0.50 mg BID for up to 4\~6 cycles (1 cycle: 3 weeks) intervention 2: Drug: Carboplatin IV, AUC of 6 mg/mL\*min, once every three weeks for up to 4\~6 cycles (1 cycle: 3 weeks) intervention 3: Drug: Paclitaxel IV, 200mg/m\^2, once every three weeks for up to 4\~6 cycles ...	intervention 1: CS-7017 intervention 2: Carboplatin intervention 3: Paclitaxel	1	Seoul \| Gangnam-gu \| South Korea \| 126.9784 \| 37.566	16	NCT01199055	1COMPLETED	2011-07-01	2010-03-01	Daiichi Sankyo Co., Ltd.	4INDUSTRY	false	false	false	null	0
[ 4 ]	27	RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The primary objectives of this trial is to evaluate the changes from baseline (Visit 2) in the 24-hour Ambulatory Blood Pressure Monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with Telmisartan 80mg/Amlodipine 5mg in patients with moderate to s...	null	Hypertension		null	1	arm 1: Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.	intervention 1: telmisartan+amlodipine fixed dose combination	1	Shanghai \| N/A \| China \| 121.45806 \| 31.22222	27	NCT01204398	1COMPLETED	2011-07-01	2010-11-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	0
[ 3 ]	11	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human beings show that this drug can make a difference in the way anti-estrogens work in hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that helps them live and grow. Studies done in the labora...	The safety run component of this trial is to determine the safety profile of the OSI-906, erlotinib and anti-endocrine treatment combination. The phase II component evaluates the antitumor activity of the combination OSI-906, erlotinib and endocrine therapy.	Hormone-sensitive Metastatic Breast Cancer		null	1	arm 1: * OSI-906 in a pill form, by mouth, twice a day (12 hours a part) * Erlotinib in a pill form, by mouth, once a day * Letrozole in a pill form, by mouth, once a day * Goserelin, by injection once per month for women who are pre-menopausal	[ 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: In a pill form by mouth, twice a day (12 hours apart) During the safety run portion of the study" * Dose level 2 = 150 mg twice a day * Dose level 1 = 100 mg twice a day * Dose level -1 = 100 mg twice a day * Dose level -2 = 100 mg twice a day intervention 2: During the safety run phase of the study: ...	intervention 1: OSI-906 intervention 2: Erlotinib intervention 3: Letrozole intervention 4: Goserelin	3	Franklin \| Tennessee \| United States \| -86.86889 \| 35.92506 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	11	NCT01205685	6TERMINATED	2011-07-01	2010-05-01	Vanderbilt-Ingram Cancer Center	7OTHER	false	false	false	null	0
[ 0 ]	69	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The aim of this study will be to determine the efficacy of this novel, lipid-containing artificial tear on the signs and symptoms of meibomian gland disease.	This investigation will involve approximately 90 MGD subjects, randomly assigned to either the Systane Balance treatment group or a control group using Optive™ Lubricant Eyedrops (Allergan), a low-viscosity artificial tear. Both arms will dose the drops four times per day and the treatment trial will be conducted for 6...	Meibomian Gland Dysfunction	dry eye, MGD, tear film break up time	null	2	arm 1: Artificial tear emulsion arm 2: Artificial tear	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Artificial tear emulsion drop intervention 2: Artificial tear eye drop	intervention 1: Systane Balance intervention 2: Optive Lubricant Eye Drops	1	Fullerton \| California \| United States \| -117.92534 \| 33.87029	69	NCT01207752	1COMPLETED	2011-07-01	2010-09-01	Southern California College of Optometry at Marshall B. Ketchum University	7OTHER	false	false	false	null	0
[ 2 ]	38	RANDOMIZED	SINGLE_GROUP	0TREATMENT	4QUADRUPLE	false	0ALL	false	The primary purpose of this Study is to help answer the following research question(s). * How does LY2189265 affect gastric emptying (the speed at which food and drink leaves the stomach) in patients with Type 2 diabetes? * How does LY2189265 affect how the body handles metformin (a drug used to treat Type 2 diabetes)...	null	Diabetes Mellitus, Type 2		null	2	arm 1: Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5. Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall. Participants regularly taking metformin will continue their normal do...	[ 2, 0 ]	2	[ 2, 0 ]	intervention 1: 1.5 mg administered subcutaneously intervention 2: Administered subcutaneously	intervention 1: LY2189265 intervention 2: Placebo	1	Glasgow \| N/A \| United Kingdom \| -4.25763 \| 55.86515	62	NCT01215968	1COMPLETED	2011-07-01	2010-09-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 4 ]	71	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline v...	null	End Stage Renal Disease (ESRD) Diabetes CAPD	ESRD Diabetes CAPD	null	2	arm 1: Dianeal only arm 2: Dianeal, Extraneal, Nutrineal	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose intervention 2: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin	intervention 1: Dianeal intervention 2: Dianeal, Extraneal, Nutrineal	16	Armenia \| N/A \| Colombia \| -75.67263 \| 4.53656 Barranquilla \| N/A \| Colombia \| -74.78132 \| 10.96854 Bogotá \| N/A \| Colombia \| -74.08175 \| 4.60971 Bucaramanga \| N/A \| Colombia \| -73.11895 \| 7.125 Cartagena \| N/A \| Colombia \| -75.49328 \| 10.39817 Cúcuta \| N/A \| Colombia \| -72.5049 \| 7.90745 Girardot \| N/A \| Colombia \| -7...	251	NCT01219959	1COMPLETED	2011-07-01	2010-10-01	Vantive Health LLC	4INDUSTRY	false	false	false	null	0
[ 2 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	1FEMALE	false	This is a multi-center, open-label, drug-drug interaction study in postmenopausal women with osteoporosis.	Approximately 27 subjects (Group A: 18; Group B: 9) will receive a 2 mg oral dose of midazolam on day 1 followed by a 24 hour PK collection. Subjects randomized to Group A will receive a single 60 mg subcutaneous (SC) dose of denosumab on day 2 administered in the abdomen. On study day 16, another 2 mg oral dose of mid...	Postmenopausal Osteoporosis	Amgen Phase 1 Postmenopausal Osteoporosis	null	2	arm 1: All 27 subjects will receive midazolam. arm 2: Eighteen (18) subjects will receive denosumab.	[ 5, 1 ]	2	[ 0, 0 ]	intervention 1: Eighteen (18) subjects will receive 1 fixed dose administration of denosumab. intervention 2: All subjects will receive two oral dose administrations of midazolam.	intervention 1: Denosumab intervention 2: Midazolam	0	null	79	NCT01221727	1COMPLETED	2011-07-01	2010-11-01	Amgen	4INDUSTRY	false	false	false	null	0
[ 3 ]	8	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.	The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function. Research exploring the use of selective serotonin reuptake inhibitors in the treatment of ...	Traumatic Brain Injury Depression	Depression Traumatic brain injury Duloxetine Cymbalta impaired cognitive function	null	2	arm 1: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously. arm 2: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously. intervention 2: Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months p...	intervention 1: Duloxetine intervention 2: Sugar pill	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	8	NCT01223001	6TERMINATED	2011-07-01	1996-09-01	Rehabilitation Hospital of Indiana	7OTHER	false	false	false	null	0
[ 0 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	true	0ALL	false	In this study the investigators will test a nutritional supplement called betaine hydrochloride to see if it can temporarily increase the stomach acid in healthy volunteers who have decreased stomach acid because they take a medicine called rabeprazole.	Investigators will evaluate the extent and time course of gastric re-acidification after oral betaine HCl in healthy volunteers with pharmacologically-induced hypochlorhydria. After betaine HCl dose, gastric pH will be continuously monitored for 2 hours.	Pharmacodynamic		null	1	arm 1: None	[ 0 ]	2	[ 7, 0 ]	intervention 1: betaine hydrochloride 1500mg po x 1 on day 5 intervention 2: rabeprazole po daily x 5 days	intervention 1: betaine hydrochloride intervention 2: Rabeprazole	1	San Francisco \| California \| United States \| -122.41942 \| 37.77493	6	NCT01237353	1COMPLETED	2011-07-01	2011-03-01	University of California, San Francisco	7OTHER	false	false	false	null	0
[ 2, 3 ]	7	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with seizures. Secondary objectives are to evaluate the safety and efficacy of a 50 mg/kg loading dose of levetiracetam in term and preterm infan...	null	Seizures	seizures neonate levetiracetam Epilepsy central nervous system diseases anticonvulsants	null	0	null	null	1	[ 0 ]	intervention 1: 50 mg/kg single loading dose of IV levetiracetam	intervention 1: levetiracetam	1	Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711	7	NCT01239212	1COMPLETED	2011-07-01	2010-09-01	Children's Hospital Medical Center, Cincinnati	7OTHER	false	false	false	null	0
[ 2, 3 ]	36	RANDOMIZED	CROSSOVER	null	2DOUBLE	true	0ALL	true	Nanotechnology is the controlled generation and manipulation of matter in dimensions less than 100 nm. Silver has been used for its bactericidal properties. The investigators propose to study the American Biotech Laboratory 32 ppm silver solution over a 14-day period in human volunteers to determine the toxicity and to...	null	Healthy		null	2	arm 1: Oral Dose of 10ppm arm 2: Oral Dose of 32ppm	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Silver nanoparticles at 10ppm intervention 2: Silver nanoparticles at 32ppm	intervention 1: 10ppm Oral Silver Particle intervention 2: 32ppm Oral Silver Particle	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	60	NCT01243320	1COMPLETED	2011-07-01	2010-12-01	University of Utah	7OTHER	false	false	false	null	0
[ 3 ]	70	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The purpose of the study is to compare safety and efficacy of Fibrin Sealant (FS) Vapor Heated (VH) S/D 500 s-apr with manual compression as a supportive treatment of local bleeding (i.e. oozing) in hepatic resection surgery when standard surgical techniques are insufficient.	null	Bleeding (Oozing) in Hepatic Resection		null	2	arm 1: Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment. arm 2: A dry surgical gauze swab will be used to apply...	[ 0, 1 ]	2	[ 0, 10 ]	intervention 1: Dosage form: spray application; dosage frequency: single application intervention 2: Dosage form: surgical gauze swab; dosage frequency: single application	intervention 1: Fibrin Sealant (FS) VH S/D 500 s-apr intervention 2: Manual compression	7	Berlin \| N/A \| Germany \| 13.41053 \| 52.52437 Essen \| N/A \| Germany \| 7.01228 \| 51.45657 Hanover \| N/A \| Germany \| 9.73322 \| 52.37052 Heidelberg \| N/A \| Germany \| 8.69079 \| 49.40768 Jena \| N/A \| Germany \| 11.5899 \| 50.92878 Leipzig \| N/A \| Germany \| 12.37129 \| 51.33962 Tübingen \| N/A \| Germany \| 9.05222 \| 48.52266	70	NCT01244425	1COMPLETED	2011-07-01	2010-11-01	Baxter Healthcare Corporation	4INDUSTRY	false	false	false	null	0
[ 5 ]	9	RANDOMIZED	FACTORIAL	9OTHER	0NONE	false	0ALL	true	Heparin/Platelet Factor 4 (PF4) antibody testing will be performed in subjects who have just undergone coronary artery bypass grafting (CABG) surgery. 30 subjects with a positive antibody result and no signs or symptoms of Heparin Induced Thrombocytopenia (HIT) will be randomized to receive argatroban and warfarin. 30 ...	This is a prospective, randomized, single center study. Patients scheduled for CABG will be screened and enrolled. Subjects positive for heparin/PF4 antibody within 24 h after CABG and without clinical suspicion of HIT will be randomized into one of two groups. An additional 30 patients with negative antibody titers wi...	Coronary Artery Bypass Graft Surgery Presence of Heparin/Platelet Factor 4 Antibody		null	3	arm 1: Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin arm 2: Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication arm 3: Post-CABG heparin PF4 antibody negative with no signs or symptoms of HI...	[ 0, 4, 4 ]	1	[ 0 ]	intervention 1: Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.	intervention 1: Argatroban and warfarin	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	8	NCT01246011	6TERMINATED	2011-07-01	2010-11-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0
[ 3 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	null	The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.	null	Endometrial Cancer		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops	intervention 1: BN83495	9	Augusta \| Georgia \| United States \| -81.97484 \| 33.47097 Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Upland \| Pennsylvania \| United States \| -75.38269 \| 39.85261 London \| Ontario \| Canada \| -81.23304 \| 42.98339 Ottawa \| Ontario \| Cana...	6	NCT01251354	6TERMINATED	2011-07-01	2010-11-01	Ipsen	4INDUSTRY	false	false	false	null	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.